Pooled Safety Analysis of Relacorilant Plus Nab-paclitaxel in Patients With Platinum-resistant Ovarian Cancer Enrolled to ROSELLA and Study 552

Olawaiye et al. • 2026 • ESMO

Read more

Meta-analysis of Relacorilant Plus Nab-paclitaxel Efficacy in Patients With Platinum-resistant Ovarian Cancer (PROC) Enrolled to ROSELLA and Study 552

Olawaiye et al. • 2026 • ESMO

Read more

Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)

Lorusso et al. • 2026 • ESMO Gyn

Read more

Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)

Shahin et al. • 2026 • ESMO Gyn

Read more

SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies

Hamid et al. • 2026 • ASCO

Read more

TRIDENT: A Phase 2 Study of Relacorilant Plus Nab-paclitaxel and Gemcitabine in Chemotherapy-naïve Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Borazanci et al. • 2026 • ASCO

Read more

Overall Survival Subgroup Analyses for Prior Taxane Use in the Phase 3 ROSELLA Trial of Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer

Gilbert et al. • 2026 • ASCO

Read more

© 2026 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube